Quality of Life in Patients With Chronic Urticaria

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03163875
Collaborator
(none)
30
14

Study Details

Study Description

Brief Summary

Urticaria is one of the most frequent presenting complaints in dermatology, allergy, and emergency departments. The term chronic urticaria (CU) is understood as the appearance of recurrent wheals more than twice a week for over 6 consecutive weeks .Urticaria is not a single disease but a reaction pattern that represents cutaneous mast cell degranulation, resulting in extravasation of plasma into the dermis. The incidence of chronic urticaria is unknown, but it is thought to occur in 0.1%-3% of the population

Condition or Disease Intervention/Treatment Phase
  • Other: Hospital Anxiety and Depression Scale

Detailed Description

Chronic urticaria signs and symptoms include: patches of red or white wheals, usually on the face, trunk, arms or legs. Wheals vary in size, change shape, and appear and fade repeatedly as the reaction runs its course. Itching is common, which may be severe. Swelling may occur that causes pain or burning (angioedema), especially inside the throat and around the eyes, cheeks, lips, hands, feet and genitals.

It is characterized by a tendency for signs and symptoms to flare with triggers such as heat, exercise and stress as well as a tendency for symptoms to recur frequently and unpredictably, sometimes for months or years The significance of chronic urticaria is sometimes trivialised because it is a non-life-threatening disease, but the condition can be very uncomfortable and interfere with sleep and daily activities. It is one of the most common and frustrating diseases for both patients and physicians Chronic urticaria has a major impact on quality of life (QoL) , with impact on activities of daily living. Chronic urticaria patients reportedly suffer considerable loss of energy, sleep disturbance and emotional upset as well as restrictions in the social life. Depression and anxiety are the most common psychiatric diagnoses. These psychiatric disorders could also influence QoL

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Quality of Life,Anxity,Depression and Quality of Sleep in Patients With Chronic Urticaria
Anticipated Study Start Date :
Jun 1, 2017
Anticipated Primary Completion Date :
Jun 10, 2018
Anticipated Study Completion Date :
Aug 1, 2018

Outcome Measures

Primary Outcome Measures

  1. measure number of patients affected with depression and anxity [one year]

    The levels of depression and anxiety will be assessed by Hospital Anxiety Depression Scale (HADS) .

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients with chronic urticaria defined as a 6-week or longer history of daily or almost daily itchy cutaneous weals with individual lesions lasting less than 24 h.

Age between 18 and 60 years.

Exclusion Criteria:

Patients who are unable to understand the questions, are unwilling to complete the questionnaire, or who have a psychiatric disorder, or obstructive sleep apnea.

Patients with malignant or central nervous system disease. Patients with cognitive impairment due to a current cerebral or psychotic illness.

Patients with current psychotherapy . glucocorticoids therapy in the last month.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
AMAbdelgawad, principle investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT03163875
Other Study ID Numbers:
  • ziad
First Posted:
May 23, 2017
Last Update Posted:
May 30, 2017
Last Verified:
May 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by AMAbdelgawad, principle investigator, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2017